Herceptin, Trastuzumab

Herceptin, Trastuzumab Newswire

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic).

Results 1 - 20 of 159 in Herceptin, Trastuzumab (generic)

  1. EORTC researchers review potential treatment options for patients with locally advanced breast cancerRead the original story w/Photo

    Yesterday | Medical News

    Treating patients with locally advanced inoperable breast cancer is an extremely difficult task. The overwhelming majority of patients treated for this disease suffer relapse and, despite the best multimodal treatment, do not survive.

    Comment?

  2. What does the future hold for treating patients with locally advanced breast cancer?Read the original story w/Photo

    Tuesday Feb 24 | EurekAlert!

    Treating patients with locally advanced inoperable breast cancer is an extremely difficult task. The overwhelming majority of patients treated for this disease suffer relapse and, despite the best multimodal treatment, do not survive.

    Comment?

  3. This hotel in Banff, in the Canadian Rockies, served as the setting...Read the original story w/Photo

    Friday Feb 20 | Synapse

    Tumors are not just solid masses of cancer cells. As those cancer cells grow and divide, they hijack all the normal cells around them for their own purposes.

    Comment?

  4. Research says approval of new drugs by NICE is 'doing more harm than good'Read the original story w/Photo

    Thursday Feb 19 | PhysOrg Weblog

    Research by health economists at the University of York has, for the first time, estimated the effects of changes in NHS expenditure on the health of all NHS patients. This research has found that the 'threshold' used by the National Institute for Health and Care Excellence when gauging the cost-effectiveness of new drugs is too high.

    Comment?

  5. Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer TherapeuticsRead the original story

    Tuesday Feb 17 | Freshnews

    Halozyme Therapeutics, Inc. today announced that the manuscript "Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy" has been published in Molecular Cancer Therapeutics . The paper expands on previously reported data in a poster presentation at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium in San Francisco, CA.

    Comment?

  6. Proposed dietary guidelines not a green light to eat what you wantRead the original story w/Photo

    Thursday Feb 12 | WTHR-TV Indianapolis

    People who follow a heart-healthy diet won't see much change in their eating habits if, as reported, this year's U.S. Dietary Guidelines report rescinds previous warnings against eating certain cholesterol-rich foods. People who follow a heart-healthy diet won't see much change in their eating habits if, as reported, this year's U.S. Dietary Guidelines report rescinds previous warnings against eating certain cholesterol-rich foods.

    Comment?

  7. Pfizer's Acquisition Of Hospira Looks GoodRead the original story w/Photo

    Monday Feb 9 | Seeking Alpha

    Hospira's pipeline is promising, an important consideration for Pfizer, which faces a patent cliff on Celebrex and has seriously reduced R&D spending since 2010. A $17 billion acquisition makes more sense from a capital allocation point of view than the previously announced buyback authorization of $11 billion.

    Comment?

  8. Analyst: Pfizer's Acquisition of Hospira Lays Foundation for Potential Generics Unit Spin-OffRead the original story w/Photo

    Monday Feb 9 | Pharmaceutical Processing

    Adam Dion, MS, GlobalData's Healthcare Industry Analyst, says: "On 5 February 2015, just days after gaining US Food and Drug Administration breakthrough approval for Ibrance in breast cancer, Pfizer entered into an agreement to purchase generic drug maker Hospira for $90 per share in cash, or approximately $17 billion, representing about a 40% premium above Hospira's stock price. The deal comes a number of months after Pfizer's failed attempt to acquire AstraZeneca, a move that signaled the company was trying to stem its losses from the patent cliff through inorganic growth means.

    Comment?

  9. Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical TrialRead the original story w/Photo

    Monday Feb 9 | GlobeNewswire

    Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced enrollment of the 700th patient in the NeuVax Phase 3 PRESENT clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.

    Comment?

  10. 5 Heart Risks for Breast Cancer PatientsRead the original story w/Photo

    Thursday Feb 5 | Business Journal

    Many medications have been proven successful in treating breast cancer, but some have also been linked to heart issues.

    Comment?

  11. Trogocytosis-mediated expression of HER2 on immune cells may be...Read the original story

    Friday Feb 6 | BioMed Central

    BackgroundTrogocytosis is defined as the transfer of cell-surface membrane proteins and membrane patches from one cell to another through contact. It is reported that human epidermal growth factor receptor 2 could be transferred from cancer cells to monocytes via trogocytosis; however, the clinical significance of this is unknown.

    Comment?

  12. Inflammatory Breast CancerRead the original story w/Photo

    Friday Feb 6 | MedicineNet

    Dr. Balentine received his undergraduate degree from McDaniel College in Westminster, Maryland. He attended medical school at the Philadelphia College of Osteopathic Medicine graduating in1983.

    Comment?

  13. Hospira v Genentech Mark 1, the AppealRead the original story

    Friday Feb 6 | IPKat

    The dispute between Hospira and Genentech in the UK courts concerning the antibody trastuzumab, more famously known as Herceptin , is getting a little confusing. We had decision Mark 1 last April in relation to a first pair of patents, and then decision Mark 2 last November in relation to a second pair.

    Comment?

  14. New molecule protects heart from toxic breast cancer drugsRead the original story w/Photo

    Tuesday Feb 3 | PhysOrg Weblog

    A new molecule has been found that protects the heart from toxic breast cancer drugs and also kills the cancerous tumor. The research from Italy addresses the burgeoning problem of heart disease in cancer survivors and is announced by the European Society of Cardiology today on World Cancer Day.

    Comment?

  15. Dartmouth scientists discover novel cancer resistance mechanismRead the original story w/Photo

    Tuesday Feb 3 | Medical News

    In the search for new approaches to treat ERBB2 positive breast cancers that have become drug-resistant, Dartmouth's Norris Cotton Cancer Center investigator Manabu Kurokawa, PhD, led a team in discovery of a novel cancer resistance mechanism with findings published in Cell Cycle . "Approximately 25% of breast cancers overexpress and depend on the protein ERBB2 for survival," said Kurokawa.

    Comment?

  16. Team discovers new mechanism of acquired resistance to breast cancer drugsRead the original story w/Photo

    Monday Feb 2 | PhysOrg Weblog

    In the search for new approaches to treat ERBB2 positive breast cancers that have become drug-resistant, Dartmouth's Norris Cotton Cancer Center investigator Manabu Kurokawa, PhD, led a team in discovery of a novel cancer resistance mechanism with findings published in Cell Cycle . "Approximately 25% of breast cancers overexpress and depend on the protein ERBB2 for survival," said Kurokawa.

    Comment?

  17. New mechanism of acquired resistance to breast cancer drugsRead the original story

    Monday Feb 2 | Science Daily

    In the search for new approaches to treat ERBB2 positive breast cancers that have become drug-resistant, researchers have discovered a novel cancer resistance mechanism. "Approximately 25% of breast cancers overexpress and depend on the protein ERBB2 for survival," said the lead investigator.

    Comment?

  18. Dartmouth Researchers Discover New Mechanism of Acquired Resistance to Breast Cancer DrugsRead the original story

    Monday Feb 2 | Newswise

    In the search for new approaches to treat ERBB2 positive breast cancers that have become drug-resistant, Dartmouth 's Norris Cotton Cancer Center investigator Manabu Kurokawa, PhD, led a team in discovery of a novel cancer resistance mechanism with findings published in Cell Cycle . "Approximately 25% of breast cancers overexpress and depend on the protein ERBB2 for survival," said Kurokawa.

    Comment?

  19. Biosimilar Monoclonal Antibodies: World Industry and Market Outlook 2015-2025Read the original story

    Monday Feb 2 | PR Log

    PRLog - Feb. 2, 2015 - LONDON -- Revenues for biosimilar monoclonal antibody therapies will exceed $4bn by 2020, predicts new study A new report by visiongain forecasts the overall world market for biosimilar monoclonal antibodies will exceed $4bn by 2020. That revenue forecast and others appear in Biosimilar Monoclonal Antibodies: World Industry and Market Outlook 2015-2025 , published in January 2015.

    Comment?

  20. Duality finger at US drug patent callRead the original story

    Wednesday Jan 28 | The Telegraph

    New Delhi, Jan. 28: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India. The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.

    Comment?